Mucopolysaccharidosis I (MPS I) manifests as a rare genetic lysosomal disorder characterized by deficient alpha-L-iduronidase enzyme function, leading to progressive glycosaminoglycan buildup throughout various anatomical systems. The healthcare treatment sector for this uncommon inherited condition has witnessed extraordinary advancement over the preceding decade, fueled by groundbreaking...